TRAIL-R1 as a novel surface marker for circulating giant cell tumor of bone.

TRAIL-R1 as a novel surface marker for circulating giant cell tumor of bone.

Oncotarget. 2017 Apr 11;:

Authors: Liu JX, Zhang ZC, Shao ZW, Pu FF, Wang BC, Zhang YK, Zeng XL, Guo XD, Yang SH, He TC

Abstract
Giant cell tumor of bone (GCT), which frequently occurs in the patients' spine, is relatively prevalent in Chinese population. A group of GCT invades into vessels and appears to be circulating tumor cells (CTCs) responsible for the distal metastasis of the primary tumor. So far the cell surface markers of GCT have not been determined. In the current study, we aimed to identify a novel CTC marker with higher specificity in GCT. TRAIL-R1+ cells were purified from GCT cell lines. The TRAIL-R1+ cells were compared with total GCT cells for tumor sphere formation, chemo-resistance, tumor formation in nude mice, and frequency of developing distal metastases. We found that TRAIL-R1+ GCT cells appeared to be highly enriched for CTCs in GCT. Compared to total GCT cells, TRAIL-R1+ GCT cells generated significantly more tumor spheres in culture, were higher chemo-resistant, and had a higher frequency of being detected in the circulation after subcutaneous transplantation as well as development of distal metastases. Thus, we conclude that TRAIL-R1+ may be a novel CTC marker in GCT. Selective elimination of TRAIL-R1+ GCT cells may improve the current GCT therapy.

PMID: 28455991 [PubMed - as supplied by publisher]

http://ift.tt/2pu2Yz6